Skip to main content
TipRanks
Go Ultimate75% OFF

Charles River Labs (CRL) AI Stock Analysis

612 Followers
CRL

Charles River Labs

(NYSE:CRL)

Select Model
Rating:62Neutral
Price Target:$358.00▲(6.70% Upside)
Action:reiterated
Date:11/09/26

The score reflects a tug-of-war between pressured financial performance (notably weak recent revenue/profitability) and healthier forward indicators: solid cash generation, an improving outlook and sentiment from the latest earnings call (raised guidance, stronger bookings/backlog, margin expansion), and a technically strong uptrend. These positives are meaningfully offset by very expensive valuation (extremely high P/E) and ongoing segment headwinds (RMS softness, delayed pricing impact, higher interest expense).

Positive Factors
DSA demand and backlog strengthStrong DSA bookings, a book-to-bill above one, and a growing backlog provide durable visibility into future service revenue. Continued demand for regulated safety assessment supports utilization, customer retention, and operating leverage across the core business.
Negative Factors
Material earnings deteriorationThe sharp revenue contraction and compressed operating profitability indicate that recent earnings power remains materially below prior levels. Until volume, cost structure, and operating margins recover sustainably, weaker profits could constrain reinvestment and reduce resilience.

Charles River Labs Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down revenue across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.

$0.00$250.00M$500.00M$750.00M$1.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

DSA is emerging as the primary growth engine — stronger bookings and a fatter backlog support management’s call for low-single-digit organic growth — while Manufacturing is generating outsized margin gains (helped by divestitures and cost actions) even as portfolio moves mute reported revenue. RMS remains the weak link, hit by North American academic/government funding and expected to decline low‑to‑mid single digits, capping near‑term top‑line. Raised EPS and cash targets lean on margin delivery, back‑loaded NHP sourcing benefits and timing of pricing recovery.

Data provided by:The Fly

Charles River Labs (CRL) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%CRL+107.01%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$16.08B
Dividend Yield
―
Average Volume (3M)
1.05M
Price to Earnings (P/E)
328.7
Beta (1Y)
0.65
Revenue Growth
-1.16%
EPS Growth
―
Country
US
Employees
19,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Charles River Labs Business Overview & Revenue Model

Company Description

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with d...

How the Company Makes Money

CRL makes money primarily by selling products and contracting services that customers use to advance research programs and move drug candidates toward clinical development. 1) Research Models and Services (RMS): - Product revenue: CRL generates reven...

Charles River Labs Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-4.65%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was predominantly positive. The company reported stronger-than-expected revenue, earnings, margins, bookings, backlog, and cash flow; raised full-year revenue and EPS guidance; and described improving biopharmaceutical demand, manufacturing momentum, strategic client expansion, and progress in modernization and scientific initiatives. The main challenges were the RMS decline, continued academic and government funding pressure, limited current pricing power, higher interest expense, and the remaining recovery in early-stage biotech activity.

Positive Updates

Strong Third-Quarter Revenue and Earnings
Third-quarter revenue increased 4.7% year-over-year to its highest level since the second quarter of 2023, exceeding the prior outlook of 1%-3% organic growth. Non-GAAP earnings per share were $3.09, up 27.2% year-over-year and above the prior outlook of $2.90-$3.00.

Negative Updates

RMS Revenue Decline
RMS revenue declined 0.6% organically to $208 million, primarily due to lower revenue for small research models in North America and lower non-human primate revenue sold to third parties, partly related to shipment timing.

Company Guidance

For 2026, Charles River expects reported revenue decline of 1.5%-2%, organic revenue growth of at least 1.5%, DSA above 2% growth, manufacturing at a mid-single-digit growth rate, and RMS at a low single-digit organic decline; operating margin expansion of approximately 120-150 basis points; non-GAAP earnings per share of $11.35-$11.55, representing 10%-12% year-over-year growth; non-GAAP tax rate of approximately 23%; net interest expense at the upper end of $103 million-$108 million; unallocated corporate costs of approximately 6% of revenue; CapEx of approximately $200 million; and free cash flow of $400 million-$420 million. For the fourth quarter, it expects DSA organic growth at mid-single-digit and manufacturing at high single-digit rates, a modest reduction in the RMS growth rate, continued sequential operating margin improvement of approximately 150 basis points, manufacturing operating margin approaching 40%, and non-GAAP earnings per share growth of approximately 30%-40% year-over-year. For 2027, it expects a gradual improvement from the organic growth rate in 2026, with revenue growth increasing to the targeted 5%-7% range starting in 2028, and operating margin improvement higher than the 75 basis point average through 2030.

Charles River Labs Financial Statement Overview

Summary

Mixed fundamentals. Income statement trends are weak (sharp TTM revenue contraction, compressed profitability with negative EBIT and losses/near-breakeven), but cash flow remains a clear strength (solid TTM operating cash flow and free cash flow) and the balance sheet is serviceable though meaningfully leveraged, making earnings recovery important.

Income Statement

34Negative

Balance Sheet

55Neutral

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.98B4.02B4.05B4.13B3.98B3.54B
Gross Profit1.31B1.23B1.33B1.50B1.46B1.33B
EBITDA293.19M410.84M581.14M1.03B986.15M820.16M
Net Income40.19M-144.34M10.30M474.62M486.23M390.98M
Balance Sheet
Total Assets7.45B7.14B7.53B8.20B7.60B7.02B
Cash, Cash Equivalents and Short-Term Investments200.38M213.77M194.61M276.77M233.91M246.30M
Total Debt2.85B3.07B2.72B3.07B3.10B3.21B
Total Liabilities4.18B3.92B4.02B4.54B4.58B4.43B
Stockholders Equity3.23B3.16B3.46B3.60B2.98B2.53B
Cash Flow
Free Cash Flow399.63M518.49M501.61M365.37M294.91M532.03M
Operating Cash Flow622.41M737.65M734.58M683.90M619.64M760.80M
Investing Cash Flow-443.19M-209.32M-245.09M-563.15M-607.92M-1.44B
Financing Cash Flow-122.95M-536.73M-550.93M-85.52M-42.40M672.60M

Charles River Labs Technical Analysis

Technical Analysis SentimentNeutral
Last Price335.52

Price Trends

50DMA312.00Positive
100DMA283.32Positive
200DMA228.34Positive

Market Momentum

MACD7.21Positive
RSI51.46Neutral
STOCH52.25Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRL, the sentiment is Neutral. The current price of 335.52 is below the 20-day moving average (MA) of 344.72, above the 50-day MA of 312.00, and above the 200-day MA of 228.34, indicating a neutral trend. The MACD of 7.21 indicates Positive momentum. The RSI at 51.46 is Neutral, neither overbought nor oversold. The STOCH value of 52.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRL.

Charles River Labs Risk Analysis

Charles River Labs disclosed 41 risk factors in its most recent earnings report. Charles River Labs reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks
1.We have in the past experienced and in the future could experience unauthorized access into our information systems.Q1, 2026
2.Our review of potential strategic alternatives may not result in an executed or consummated transaction or other strategic alternative, and the process of reviewing strategic alternatives or the outcome could adversely affect our business.Q4, 2025
3.Uncertainties with respect to the development, deployment, and use of artificial intelligence present new risks and challenges and could adversely affect our business and reputation.Q4, 2025

Charles River Labs Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CRL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MEDPMEDP84Outperform$18.13B35.4799.76%―20.35%25.24%
TMOTMO77Outperform$256.15B36.4013.31%0.27%8.27%9.59%
LHLH75Outperform$30.24B30.3011.54%0.77%6.02%19.63%
IQVIQV74Outperform$43.63B31.8521.82%―8.88%13.11%
ICLRICLR71Outperform$14.34B32.764.85%―0.67%43.70%
CRLCRL62Neutral$16.08B328.751.32%―-1.16%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%CRLICLRLHTMOIQVMEDPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CRL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CRLCharles River Laboratories Intl335.52173.88107.57%
ICLRIcon Plc191.4032.5920.52%
LHLabcorp Holdings Inc.372.46114.5244.40%
TMOThermo Fisher Scientific691.33119.5520.91%
IQVIQVIA Holdings264.7347.2521.73%
MEDPMedpace Holdings Inc648.2056.029.46%

Charles River Labs Corporate Events

M&A Transactions

Charles River Labs to Acquire Frontage Bioanalysis Operations

Positive
Nov 9, 2026

On November 9, 2026, Charles River announced definitive agreements to acquire Frontage Holdings’ bioanalysis and DMPK operations in Exton, Pennsylvania, for approximately $470 million in cash. The assets include bioanalysis, biomarker and DMPK testin...

Business Operations and StrategyFinancial Disclosures

Charles River Labs Unveils New Strategic Growth Vision

Positive
Sep 24, 2026

On September 24, 2026, Charles River Laboratories used its Investor Day to unveil a refreshed “Pathway to Purpose” strategic vision aimed at modernizing operations, strengthening its scientific portfolio, and enhancing its client-centric model to rei...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026